454 Life Sciences (TM), founded in 2000 and based in Branford, Connecticut, is a Roche Diagnostics company that provides clients with proprietary high-throughput nucleotide sequencing instrumentation and services. The firm's platform supports the sequencing of entire genomes and the ultra-deep sequencing of target genes. Only a single sample preparation is required for the sequencing of entire genes. 454 Life Sciences' PicoTiterPlate (TM) device employs patented light emitting sequencing chemistries, producing millions of nucleotide bases within hours. The technology increases sequencing capacity 100-fold. 454 Life Sciences is known for its Genome Sequencer 20 (TM) and Genome Sequencer FLX (TM) systems. The Genome Sequencer 20 instrumentation package includes software, reagents, consumables, and accessories. The software supports the mapping and assembly of genomes up to 50 megabases. The Genome Sequencer FLX system supports library construction, amplification, and sequencing processes. The system's software includes mapping, amplicon variant analysis, and other features. The 454 Sequencing (TM) Center provides clients worldwide with sample sequencing services. 454 Life Sciences submitted a complete adenovirus sequence to GenBank in 2003. Pharmaceuticals and diagnostics technology firm Roche Diagnostics acquired 454 Life Sciences from CuraGen in 2007. Prior to the acquisition, Roche was the exclusive worldwide distributor of 454 Life Sciences' Genome Sequencer systems and reagents. Roche Diagnostics is based in Basel, Switzerland.